GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK has acquired exclusive rights from Syndivia for an antibody-drug conjugate (ADC) targeting advanced prostate cancer in a deal worth up to £268 million.
The agreement reinforces GSK's oncology pipeline and provides Syndivia with the scale to progress its promising asset. The ADC, developed by the France-based biotech firm, has shown enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
GSK noted that the therapy addresses a significant unmet need, given the limited targeted treatment options for metastatic castration-resistant prostate cancer.
The deal reflects GSK's push to broaden its oncology pipeline.
Author's summary: GSK acquires rights to Syndivia's ADC for prostate cancer.